Rezultati pretraživanja
  1. FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ for the Treatment of -

  2. 21. srp 2019.

    CLR131 achieves fast track designation from FDA for relapsed myeloma and DLBCL. A phospholipid drug conjugate (PDC) which targets iodine-131 to cancer cells. Interesting to see how it fares against bispecifics and ADCs.

  3. 14. sij 2017.

    saw jpm17. Could be prom. tech., first data good. Biggest problem: they are moving far too slow bec of very low cash.

  4. 14. sij 2017.

    can't find a scientific publication where your statement'PFS better than with dara'is pls

  5. 14. ožu 2019.

    buy the dips leading to 2nd quarter 2019, Routing for successful phase 2 top line data.

    Prikaži ovu nit
  6. Odgovor korisnicima

    Hi there! Any new information about or the company in general can be found on our website and in our corporate presentation. Thanks for your question!

  7. 25. srp 2018.

    this is the way to make investors loose trust. Or do you have another argumention why you omitted a patient from response rate calculation for and did not mention it?

    Prikaži ovu nit
  8. 27. sij

    : Cellectar Biosciences to Host a Clinical Data Call with Its Phase 2 Lead Investigator on February 19, 2020

  9. 1. stu 2016.
  10. 23. velj 2017.
  11. 7. sij
  12. 30. sij

    Do you have our upcoming clinical data call on your calendar yet? If not, click the link for more information about the call: For more info about , visit

  13. 22. sij

    “...drop the payload internally, inside of the cell. It’s the ultimate Trojan Horse, if you will, when you think about our delivery platform.”

  14. 10. kol 2016.
  15. 10. pro 2019.
  16. "...this is a unique option for those with MM... CLR 131 falls into a niche category for patients with MM... This is a whole new therapeutic option for [these] patients”

  17. 19. tra 2017.
  18. 28. sij

    From the interview with Dr. Laura Finn: “What I like about this drug, and especially in multiple myeloma, is its safety and its very low incidence of side effects.”

  19. 12. srp 2019.

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.